---
title: Comparing Two Indirect Pulp Capping Agents for Permanent Teeth
nct_id: NCT05425368
overall_status: UNKNOWN
phase: NA
sponsor: Cairo University
study_type: INTERVENTIONAL
primary_condition: Deep Caries
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05425368.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05425368"
ct_last_update_post_date: 2022-06-21
last_seen_at: "2026-05-12T06:03:47.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparing Two Indirect Pulp Capping Agents for Permanent Teeth

**Official Title:** Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Mineral Trioxide Aggregate as Indirect Pulp Capping Agents in Deeply Carious Young Permanent Molars Randomized Controlled Clinical Trial

**NCT ID:** [NCT05425368](https://clinicaltrials.gov/study/NCT05425368)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Cairo University
- **Conditions:** Deep Caries
- **Start Date:** 2022-08-01
- **Completion Date:** 2023-12
- **CT.gov Last Update:** 2022-06-21

## Brief Summary

Aim of the study:

To evaluate clinical and radiographic success rates of silver diamine fluoride versus mineral trioxide aggregate as indirect pulp capping agents in deeply carious young first permanent molars.

## Detailed Description

Indirect pulp treatment has become a common maneuver in vital pulp therapy in recent years and is a procedure performed in teeth with deep carious lesions approximating the pulp but without any signs or symptoms of irreversible pulpal changes.

Silver Diamine Fluoride is used to arrest caries lesions in primary teeth but according to the AAPD,2021 more research is needed on the use of SDF to arrest caries lesions in permanent teeth.

## Eligibility

- **Minimum age:** 9 Years
- **Maximum age:** 14 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient and parent showing cooperation and compliance.
* Children 9-14 years old
* Vital deeply carious young first permanent molar(s) with complete root formation
* Asymptomatic teeth or without clinical symptoms of spontaneous pain
* Both genders will be included.

Exclusion Criteria:

* Children unable to return for recall visits.
* Any clinical signs of irreversible pulpitis or pulp necrosis (spontaneous pain, pain on percussion, abscess, sinus).
* Any radiographic sign of irreversible pulp pathologies or pulp necrosis (periapical radiolucency, internal or external root resorption)
```

## Arms

- **silver diamine fluoride group** (EXPERIMENTAL) — partial caries removal will be carried out then Silver Diamine Fluoride will be applied as indirect pulp capping agent and rubbed for 1 minute followed by Glass ionomer filling
- **mineral trioxide aggregate group** (ACTIVE_COMPARATOR) — partial caries removal will be carried out then mineral trioxide aggregate will be placed as indirect pulp capping agent followed by glass ionomer filling

## Interventions

- **Silver diamine fluoride** (DRUG) — First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
- **Mineral trioxide aggregate** (DRUG) — First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.

## Primary Outcomes

- **Dentin bridge formation** _(time frame: 6 months)_ — Dentin bridge formation will be measured in millimeters on standardized digital radiographs taken by Digital Radiographic examination

## Secondary Outcomes

- **Postoperative pain** _(time frame: 1 week)_
- **Absence of sinus or fistula** _(time frame: 3 months)_
- **Absence of sinus or fistula** _(time frame: 6 months)_
- **radiographic success** _(time frame: 6 months)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05425368.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05425368*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*